VBI Vaccines (NASDAQ:VBIV) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a research report sent to investors on Saturday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

VBI Vaccines Trading Up 1.7 %

NASDAQ:VBIV opened at $0.60 on Friday. The company’s 50-day moving average price is $0.61 and its 200-day moving average price is $0.61. The company has a market cap of $17.21 million, a P/E ratio of -0.05 and a beta of 1.90. VBI Vaccines has a twelve month low of $0.45 and a twelve month high of $3.47.

About VBI Vaccines

VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.